463 results on '"Mosepele, Mosepele"'
Search Results
2. Quantitative outcomes of a type 2 single arm hybrid effectiveness implementation pilot study for hypertension-HIV integration in Botswana
- Author
-
Moshomo, Thato, Gaolathe, Tendani, Ramotsababa, Mareko, Molefe-Baikai, Onkabetse Julia, Mogaetsho, Edwin, Dintwa, Evelyn, Gala, Pooja, Ponatshego, Ponego, Bogart, Laura M., Youssouf, Nabila, Seipone, Khumo, Van Pelt, Amelia E., Bennett, Kara, Jaffar, Shabbar, Ilias, Maliha, Tonwe, Veronica, Hurwitz, Kathleen Wirth, Kebotsamang, Kago, Steger-May, Karen, Hirschhorn, Lisa R., and Mosepele, Mosepele
- Published
- 2024
- Full Text
- View/download PDF
3. High prevalence of albuminuria among adult males living with HIV in Botswana
- Author
-
Mosepele, Mosepele, Ponatshego, Ponego, Molebatsi, Kesaobaka, Williams, Christopher, Mokgatlhe, Lucky, Lockman, Shahin, Youssouf, Nabila, Gross, Robert, Jarvis, Joseph, Wang, Duolao, and Jaffar, Shabbar
- Published
- 2024
- Full Text
- View/download PDF
4. A mixed methods approach identifying facilitators and barriers to guide adaptations to InterCARE strategies: an integrated HIV and hypertension care model in Botswana
- Author
-
Gala, Pooja, Ponatshego, Ponego, Bogart, Laura M., Youssouf, Nabila, Ramotsababa, Mareko, Van Pelt, Amelia E., Moshomo, Thato, Dintwa, Evelyn, Seipone, Khumo, Ilias, Maliha, Tonwe, Veronica, Gaolathe, Tendani, Hirschhorn, Lisa R., and Mosepele, Mosepele
- Published
- 2024
- Full Text
- View/download PDF
5. Age and healthy lifestyle behavior’s disparities and similarities on knowledge of myocardial infarction symptoms and risk factors among public and outpatients in a resource-limited setting, cross-sectional study in greater Gaborone, Botswana
- Author
-
Ookeditse, Ookeditse, Ookeditse, Kebadiretse K., Motswakadikgwa, Thusego R., Masilo, Gosiame, Bogatsu, Yaone, Lekobe, Baleufi C., Mosepele, Mosepele, Schirmer, Henrik, and Johnsen, Stein H.
- Published
- 2024
- Full Text
- View/download PDF
6. HIV-associated gut microbial alterations are dependent on host and geographic context
- Author
-
Rocafort, Muntsa, Gootenberg, David B., Luévano, Jr., Jesús M., Paer, Jeffrey M., Hayward, Matthew R., Bramante, Juliet T., Ghebremichael, Musie S., Xu, Jiawu, Rogers, Zoe H., Munoz, Alexander R., Okello, Samson, Kim, June-Ho, Sentongo, Ruth, Wagubi, Robert, Lankowski, Alex, Maruapula, Segametsi, Zhao, Guoyan, Handley, Scott A., Mosepele, Mosepele, Siedner, Mark J., and Kwon, Douglas S.
- Published
- 2024
- Full Text
- View/download PDF
7. Self-reported cardiovascular disease risk factor screening among people living with HIV vs. members of the general population in Botswana: a community-based study
- Author
-
Molefe-Baikai, Onkabetse Julia, Kebotsamang, Kago, Modisawakgomo, Pinkie, Tlhakanelo, John Thato, Motlhatlhedi, Keneilwe, Moshomo, Thato, Youssouf, Nabila Farah, Masupe, Tiny, Gaolathe, Tendani, Tapela, Neo, Lockman, Shahin, and Mosepele, Mosepele
- Published
- 2024
- Full Text
- View/download PDF
8. Designing an implementation science clinical trial to integrate hypertension and cardiovascular diseases care into existing HIV services package in Botswana (InterCARE)
- Author
-
Nabila Youssouf, Gaone Edwin Mogaetsho, Thato Moshomo, Tendani Gaolathe, Ponego Ponatshego, Mareko Ramotsababa, Onkabetse Julia Molefe-Baikai, Evelyn Dintwa, Tsaone Kiki, Amelia E. Van Pelt, Karen Steger-May, Laura M. Bogart, Shabbar Jaffar, Pooja Gala, Duolao Wang, Khumo Seipone, Kara Bennett, Kathleen Wirth Hurwitz, Kago Kebotsamang, Lisa R. Hirschhorn, and Mosepele Mosepele
- Subjects
HIV ,Hypertension ,Cardiovascular disease ,Botswana ,Care integration ,Implementation research ,Medicine (General) ,R5-920 - Abstract
Abstract Background Despite success in HIV treatment, diagnosis and management of hypertension (HTN) and cardiovascular disease (CVD) remains suboptimal among people living with HIV (PLWH) in Botswana, with an overall HTN control of only 19% compared to 98% HIV viral suppressed. These gaps persist despite CVD primary care national guidelines and availability of free healthcare including antihypertensive medications. Our study aims to develop and test strategies to close the HTN care gap in PLWH, through integration into HIV care, leveraging the successful national HIV care and treatment program and strategies. Methods The InterCARE trial is a cluster randomized controlled hybrid type 2 effectiveness-implementation trial at 14 sites designed to enroll 4652 adults living with HIV and HTN plus up to 2326 treatment partners. Primary outcomes included effectiveness (HTN control) and implementation outcomes using the Reach Effectiveness Adoption Implementation and Maintenance framework, with explanatory mixed methods used to understand variability in outcomes. InterCARE trial’s main strategies include healthcare worker HTN and CVD care training plus long-term practice facilitation, electronic health record (EHR) documentation of key indicators and use of reminders, and use of treatment partners to provide social support to people living with HIV and HTN. InterCARE started with formative research to identify contextual factors influencing care gaps using the Consolidated Framework for Implementation Research. Results were used to adapt initial and develop additional implementation strategies to address barriers and leverage facilitators. The package was pilot tested in two clinics, with findings used to further adapt or add strategies for the clinical trial. Discussion If successful, the InterCARE model can be scaled up to HIV clinics nationwide to improve diagnosis, management, and support in Botswana. The trial will provide insights for scale-up of HTN integration into HIV care in the region. Trial registration ClinicalTrials.gov reference NCT05414526. Registered 18 May 2022, https://clinicaltrials.gov/study/NCT05414526?term=NCT05414526.&rank=1 .
- Published
- 2024
- Full Text
- View/download PDF
9. Quantitative outcomes of a type 2 single arm hybrid effectiveness implementation pilot study for hypertension-HIV integration in Botswana
- Author
-
Thato Moshomo, Tendani Gaolathe, Mareko Ramotsababa, Onkabetse Julia Molefe-Baikai, Edwin Mogaetsho, Evelyn Dintwa, Pooja Gala, Ponego Ponatshego, Laura M. Bogart, Nabila Youssouf, Khumo Seipone, Amelia E. Van Pelt, Kara Bennett, Shabbar Jaffar, Maliha Ilias, Veronica Tonwe, Kathleen Wirth Hurwitz, Kago Kebotsamang, Karen Steger-May, Lisa R. Hirschhorn, and Mosepele Mosepele
- Subjects
Hypertension ,HIV ,Integration ,Implementation ,Pilot study ,Botswana ,Medicine (General) ,R5-920 - Abstract
Abstract Background Successful HIV treatment programs have turned HIV into a chronic condition, but noncommunicable diseases such as hypertension jeopardize this progress. Hypertension control rates among people with HIV (PWH) are low owing to gaps in patient awareness, diagnosis, effective treatment, and management of both conditions at separate clinic visits. Integrated management, such as in our study, InterCARE, can enhance HIV-hypertension integration and blood pressure (BP) control. Methods Our pilot study was conducted in two Botswana HIV clinics between October 2021 and November 2022. Based on our formative work, we adopted three main strategies; Health worker training on HTN/cardiovascular disease (CVD) management, adaptation of HIV Electronic Health Record (EHR) for HTN/CVD care, and use of treatment partners to support PWH with hypertension for implementation. We employed the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework to assess implementation effectiveness and outcomes for BP control at baseline, 6 and 12 months. HIV viral load (VL) suppression was also measured to assess impact of integration on HIV care. Results We enrolled 290 participants; 35 (12.1%) were lost to follow-up, leaving 255 (87.9%) at 12-months. Median age was 54 years (IQR 46–62), and 77.2% were females. Our interventions significantly improved BP control to
- Published
- 2024
- Full Text
- View/download PDF
10. A mixed methods approach identifying facilitators and barriers to guide adaptations to InterCARE strategies: an integrated HIV and hypertension care model in Botswana
- Author
-
Pooja Gala, Ponego Ponatshego, Laura M. Bogart, Nabila Youssouf, Mareko Ramotsababa, Amelia E. Van Pelt, Thato Moshomo, Evelyn Dintwa, Khumo Seipone, Maliha Ilias, Veronica Tonwe, Tendani Gaolathe, Lisa R. Hirschhorn, and Mosepele Mosepele
- Subjects
HIV ,Hypertension ,Low- and middle- income countries ,Integrated care ,Botswana ,Implementation science ,Medicine (General) ,R5-920 - Abstract
Abstract Background Botswana serves as a model of success for HIV with 95% of people living with HIV (PLWH) virally suppressed. Yet, only 19% of PLWH and hypertension have controlled blood pressure. To address this gap, InterCARE, a care model that integrates HIV and hypertension care through a) provider training; b) adapted electronic health record; and c) treatment partners (peer support), was designed. This study presents results from our baseline assessment of the determinants and factors used to guide adaptations to InterCARE implementation strategies prior to a hybrid type 2 effectiveness-implementation study. Methods This study employed a convergent mixed methods design across two clinics (one rural, one urban) to collect quantitative and qualitative data through facility assessments, 100 stakeholder surveys (20 each PLWH and hypertension, existing HIV treatment partners, clinical healthcare providers (HCPs), and 40 community leaders) and ten stakeholder key informative interviews (KIIs). Data were analyzed using descriptive statistics and deductive qualitative analysis organized by the Consolidated Framework for Implementation Research (CFIR) and compared to identify areas of convergence and divergence. Results Although 90.3% of 290 PLWH and hypertension at the clinics were taking antihypertensive medications, 52.8% had uncontrolled blood pressure. Results from facility assessments, surveys, and KIIs identified key determinants in the CFIR innovation and inner setting domains. Most stakeholders (> 85%) agreed that InterCARE was adaptable, compatible and would be successful at improving blood pressure control in PLWH and hypertension. HCPs agreed that there were insufficient resources (40%), consistent with facility assessments and KIIs which identified limited staffing, inconsistent electricity, and a lack of supplies as key barriers. Adaptations to InterCARE included a task-sharing strategy and expanded treatment partner training and support. Conclusions Integrating hypertension services into HIV clinics was perceived as more advantageous for PLWH than the current model of hypertension care delivered outside of HIV clinics. Identified barriers were used to adapt InterCARE implementation strategies for more effective intervention delivery. Trial registration ClinicalTrials.gov, ClinicalTrials.gov Identifier: NCT05414526 . Registered 18 May 2022 – Retrospectively registered.
- Published
- 2024
- Full Text
- View/download PDF
11. Pilot Test of Mopati, a Multi-Level Adherence Intervention for People Living with HIV and Their Treatment Partners in Botswana
- Author
-
Bogart, Laura M., Phaladze, Nthabiseng, Kgotlaetsile, Keonayang, Klein, David J., Goggin, Kathy, and Mosepele, Mosepele
- Published
- 2023
- Full Text
- View/download PDF
12. HIV-associated gut microbial alterations are dependent on host and geographic context
- Author
-
Muntsa Rocafort, David B. Gootenberg, Jesús M. Luévano, Jeffrey M. Paer, Matthew R. Hayward, Juliet T. Bramante, Musie S. Ghebremichael, Jiawu Xu, Zoe H. Rogers, Alexander R. Munoz, Samson Okello, June-Ho Kim, Ruth Sentongo, Robert Wagubi, Alex Lankowski, Segametsi Maruapula, Guoyan Zhao, Scott A. Handley, Mosepele Mosepele, Mark J. Siedner, and Douglas S. Kwon
- Subjects
Science - Abstract
Abstract HIV-associated changes in intestinal microbiota are believed to be important drivers of disease progression. However, the majority of studies have focused on populations in high-income countries rather than in developing regions where HIV burden is greatest. To better understand the impact of HIV on fecal microbiota globally, we compare the fecal microbial community of individuals in the U.S., Uganda, and Botswana. We identify significant bacterial taxa alterations with both treated and untreated HIV infection with a high degree of uniqueness in each cohort. HIV-associated taxa alterations are also significantly different between populations that report men who have sex with men (MSM) behavior and non-MSM populations. Additionally, while we find that HIV infection is consistently associated with higher soluble markers of immune activation, most specific bacterial taxa associated with these markers in each region are not shared and none are shared across all three geographic locations in our study. Our findings demonstrate that HIV-associated changes in fecal microbiota are overall distinct among geographical locations and sexual behavior groups, although a small number of taxa shared between pairs of geographic locations warrant further investigation, highlighting the importance of considering host context to fully assess the impact of the gut microbiome on human health and disease.
- Published
- 2024
- Full Text
- View/download PDF
13. Self-reported cardiovascular disease risk factor screening among people living with HIV vs. members of the general population in Botswana: a community-based study
- Author
-
Onkabetse Julia Molefe-Baikai, Kago Kebotsamang, Pinkie Modisawakgomo, John Thato Tlhakanelo, Keneilwe Motlhatlhedi, Thato Moshomo, Nabila Farah Youssouf, Tiny Masupe, Tendani Gaolathe, Neo Tapela, Shahin Lockman, and Mosepele Mosepele
- Subjects
Cardiovascular disease risk factors ,HIV ,Screening ,PLWH ,Botswana ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Morbidity and mortality due to cardiovascular diseases (CVDs) are high and increasing in low- and middle-income countries. People living with HIV (PLWH) are more likely to experience CVD than members of the general population. Therefore, we aimed to assess whether PLWH were more likely to have previously been screened for cardiovascular disease risk factors (CVDRFs) than people without HIV. Methods A population-based, cross-sectional study was conducted among individuals aged 16 to 68 years across 22 communities in Botswana from February to August 2017 as part of a larger community-based cluster randomized HIV treatment-as-prevention trial. Participants were asked if they had been screened for and counselled on cardiovascular disease risk factors (history of hypertension or blood pressure check, blood glucose and cholesterol measurements, weight check and weight control, tobacco smoking and cessation, alcohol use and physical activity) in the preceding 3 years. HIV testing was offered to those with an unknown HIV status. Multiple logistic regression analysis controlling for age and sex was used to assess the relationship between CVDRF screening and HIV status. Results Of the 3981 participants enrolled, 2547 (64%) were female, and 1196 (30%) were PLWH (93% already on antiretroviral therapy [ART]). PLWH were more likely to report previous screening for diabetes (25% vs. 19%, p < 0.001), elevated cholesterol (17% vs. 12%, p < 0.001) and to have had their weight checked (76% vs. 55%, p < 0.001) than HIV-uninfected participants. PLWH were also more likely to have received counselling on salt intake (42% vs. 33%, p < 0.001), smoking cessation (66% vs. 46%, p < 0.001), weight control (38% vs. 29%, p < 0.001), physical activity (46% vs. 34%, p < 0.001) and alcohol consumption (35% vs. 23%, p < 0.001) than their HIV-uninfected counterparts. Overall, PLWH were more likely to have received screening for and/or counselling on CVDRFs (adjusted odds ratio 1.84, 95% CI: 1.46–2.32, p < 0.001). Conclusion PLWH were almost two times more likely to have been previously screened for CVDRFs than those without HIV, indicating a need for universal scale-up of integrated management and prevention of CVDs in the HIV-uninfected population.
- Published
- 2024
- Full Text
- View/download PDF
14. Standard of care in advanced HIV disease: review of HIV treatment guidelines in six sub-Saharan African countries
- Author
-
Thomas C. Scheier, Nabila Youssouf, Mosepele Mosepele, Cecilia Kanyama, Olukemi Adekanmbi, Sulaiman Lakoh, Conrad K. Muzoora, Graeme Meintjes, Dominik Mertz, John W. Eikelboom, and Sean Wasserman
- Subjects
Advanced HIV disease ,Standard of care ,Sub-Saharan Africa ,REVIVE trial ,WHO ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background The World Health Organization (WHO) recommends an evidence-based package of care to reduce mortality and morbidity among people with advanced HIV disease (AHD). Adoption of these recommendations by national guidelines in sub-Saharan Africa is poorly documented. We aimed to review national guidelines for AHD management across six selected countries in sub-Saharan Africa for benchmarking against the 2021 WHO recommendations. Methods We reviewed national guidelines from six countries participating in an ongoing randomized controlled trial recruiting people with AHD. We extracted information addressing 18 items of AHD diagnosis and management across the following domains: [1] Definition of AHD, [2] Screening, [3] Prophylaxis, [4] Supportive care, and [5] HIV treatment. Data from national guideline documents were compared to the 2021 WHO consolidated guidelines on HIV and an agreement score was produced to evaluate extent of guideline adoption. Results The distribution of categories of agreement varied for the national documents. Four of the six countries addressed all 18 items (Malawi, Nigeria, Sierra Leone, Uganda). Overall agreement with the WHO 2021 guidelines ranged from 9 to 15.5 out of 18 possible points: Malawi 15.5 points, Nigeria, and Sierra Leone 14.5 points, South Africa 13.5 points, Uganda 13.0 points and Botswana with 9.0 points. Most inconsistencies were reported for the delay of antiretroviral therapy (ART) in presence of opportunistic diseases. None of the six national guidelines aligned with WHO recommendations around ART timing in patients with tuberculosis. Agreement correlated with the year of publication of the national guideline. Conclusion National guidelines addressing the care of advanced HIV disease in sub-Saharan Africa are available. Besides optimal timing for start of ART in presence of tuberculosis, most national recommendations are in line with the 2021 WHO standards.
- Published
- 2023
- Full Text
- View/download PDF
15. Standard of care in advanced HIV disease: review of HIV treatment guidelines in six sub-Saharan African countries
- Author
-
Scheier, Thomas C., Youssouf, Nabila, Mosepele, Mosepele, Kanyama, Cecilia, Adekanmbi, Olukemi, Lakoh, Sulaiman, Muzoora, Conrad K., Meintjes, Graeme, Mertz, Dominik, Eikelboom, John W., and Wasserman, Sean
- Published
- 2023
- Full Text
- View/download PDF
16. Prevalence and control of hypertension in a high HIV-prevalence setting, insights from a population based study in Botswana
- Author
-
Mosepele, Mosepele, Bennett, Kara, Gaolathe, Tendani, Makhema, Joseph M., Mmalane, Mompati, Holme, Molly Pretorius, Lebelonyane, Refeletswe, Ometoruwa, Omolola, Mills, Lisa A., Powis, Kathleen M., Leidner, Jean, Jarvis, Joseph N., Tapela, Neo M., Masupe, Tiny, Mokgatlhe, Lucky, Triant, Virginia A., Wirth, Kathleen E., Moshomo, Thato, and Lockman, Shahin
- Published
- 2023
- Full Text
- View/download PDF
17. Development and validation of quantitative PCR assays for HIV-associated cryptococcal meningitis in sub-Saharan Africa: a diagnostic accuracy study
- Author
-
Goodall, J, Mawoko, N, Milburn, J, Mmipi, R, Muthoga, C, Ponatshego, P, Rulaganyang, I, Seatla, K, Tlhako, N, Tsholo, K, April, S, Bekiswa, A, Boloko, L, Bookholane, H, Crede, T, Davids, L, Goliath, R, Hlungulu, S, Hoffman, R, Kyepa, H, Masina, N, Maughan, D, Mnguni, T, Moosa, S, Morar, T, Mpalali, M, Naude, J, Oliphant, I, Sayed, S, Sebesho, L, Shey, M, Swanepoel, L, Chasweka, M, Chimang’anga, W, Chimphambano, T, Dziwani, E, Gondwe, E, Kadzilimbile, A, Kateta, S, Kossam, E, Kukacha, C, Lipenga, B, Ndaferankhande, J, Ndalama, M, Shah, R, Singini, A, Stott, K, Zambasa, A, Banda, T, Chikaonda, T, Chitulo, G, Chiwoko, L, Chome, N, Gwin, M, Kachitosi, T, Kamanga, B, Kazembe, M, Kumwenda, E, Kumwenda, M, Maya, C, Mhango, W, Mphande, C, Msumba, L, Munthali, T, Ngoma, D, Nicholas, S, Simwinga, L, Stambuli, A, Tegha, G, Zambezi, J, Ahimbisibwe, C, Akampurira, A, Alice, A, Cresswell, F, Gakuru, J, Kiiza, D, Kisembo, J, Kwizera, R, Kugonza, F, Laker, E, Luggya, T, Lule, A, Musubire, A, Muyise, R, Namujju, O, Ndyetukira, J, Nsangi, L, Okirwoth, M, Sadiq, A, Tadeo, K, Tukundane, A, Williams, D, Atwine, L, Buzaare, P, Collins, M, Emily, N, Inyakuwa, C, Kariisa, S, Mwesigye, J, Niwamanya, S, Rodgers, A, Rukundo, J, Rwomushana, I, Ssemusu, M, Stead, G, Boyd, K, Gondo, S, Kufa, P, Makaha, E, Moyo, C, Mtisi, T, Mudzingwa, S, Mwarumba, T, Zinyandu, T, Dromer, F, Johnstone, P, Hafeez, S, Mbangiwa, Tshepiso, Sturny-Leclère, Aude, Lechiile, Kwana, Kajanga, Cheusisime, Boyer-Chammard, Timothée, Hoving, Jennifer C, Leeme, Tshepo, Moyo, Melanie, Youssouf, Nabila, Lawrence, David S, Mwandumba, Henry, Mosepele, Mosepele, Harrison, Thomas S, Jarvis, Joseph N, Lortholary, Olivier, and Alanio, Alexandre
- Published
- 2024
- Full Text
- View/download PDF
18. Molecular Characterization of Hepatitis B Virus in People Living with HIV in Rural and Peri-Urban Communities in Botswana
- Author
-
Bonolo B. Phinius, Wonderful T. Choga, Motswedi Anderson, Margaret Mokomane, Irene Gobe, Tsholofelo Ratsoma, Basetsana Phakedi, Gorata Mpebe, Lynnette Bhebhe, Tendani Gaolathe, Mosepele Mosepele, Joseph Makhema, Roger Shapiro, Shahin Lockman, Rosemary Musonda, Sikhulile Moyo, and Simani Gaseitsiwe
- Subjects
hepatitis B virus ,occult hepatitis B ,genotypes ,escape mutations ,Botswana ,Africa ,Biology (General) ,QH301-705.5 - Abstract
(1) Background: Hepatitis B virus (HBV) sequencing data are important for monitoring HBV evolution. We aimed to molecularly characterize HBV sequences from participants with HBV surface antigen-positive (HBsAg+) serology and occult hepatitis B infection (OBI+). (2) Methods: We utilized archived plasma samples from people living with human immunodeficiency virus (PLWH) in Botswana. HBV DNA was sequenced, genotyped and analyzed for mutations. We compared mutations from study sequences to those from previously generated HBV sequences in Botswana. The impact of OBI-associated mutations on protein function was assessed using the Protein Variation Effect Analyzer. (3) Results: Sequencing success was higher in HBsAg+ than in OBI+ samples [86/128 (67.2%) vs. 21/71 (29.2%)]. Overall, 93.5% (100/107) of sequences were genotype A1, 2.8% (3/107) were D3 and 3.7% (4/107) were E. We identified 13 escape mutations in 18/90 (20%) sequences with HBsAg coverage, with K122R having the highest frequency. The mutational profile of current sequences differed from previous Botswana HBV sequences, suggesting possible mutational changes over time. Mutations deemed to have an impact on protein function were tpQ6H, surfaceV194A and preCW28L. (4) Conclusions: We characterized HBV sequences from PLWH in Botswana. Escape mutations were prevalent and were not associated with OBI. Longitudinal HBV studies are needed to investigate HBV natural evolution.
- Published
- 2024
- Full Text
- View/download PDF
19. Near‐complete genome of SARS‐CoV‐2 Delta variant of concern identified in a symptomatic dog (Canis lupus familiaris) in Botswana
- Author
-
Wonderful T. Choga, Samantha L. Letsholo, Chandapiwa Marobela‐Raborokgwe, Irene Gobe, Mbatshi Mazwiduma, Dorcas Maruapula, John Rukwava, Mary Gorettie Binta, Boitumelo J. L Zuze, Legodile Koopile, Kedumetse Seru, Patience Motshosi, Ontlametse Thato Bareng, Botshelo Radibe, Pamela Smith‐Lawrence, Kutlo Macheke, Lesego Kuate‐Lere, Modisa S. Motswaledi, Mpaphi B. Mbulawa, Mogomotsi Matshaba, Kereng V. Masupu, Shahin Lockman, Roger Shapiro, Joseph Makhema, Mosepele Mosepele, Simani Gaseitsiwe, and Sikhulile Moyo
- Subjects
Africa ,Botswana ,COVID‐19 ,dog ,next‐generation sequencing (NGS) ,SARS‐CoV‐2 ,Veterinary medicine ,SF600-1100 - Abstract
Abstract We sought to investigate whether SARS‐CoV‐2 was present, and to perform full‐length genomic sequencing, in a 5‐year‐old male crossbreed dog from Gaborone, Botswana that presented overt clinical signs (flu‐like symptoms, dry hacking cough and mild dyspnoea). It was only sampled a posteriori, because three adult owners were diagnosed with SARS‐CoV‐2 infection. Next‐generation sequencing based on Oxford Nanopore Technology (ONT) was performed on amplicons that were generated using a reverse transcriptase real‐time polymerase chain reaction (RT‐qPCR) of confirmed positive SARS‐CoV‐2 nasopharyngeal and buccal swabs, as well as a bronchoalveolar lavage with mean real cycle threshold (qCt) value of 36 based on the Nucleocapsid (N) gene. Descriptive comparisons to known sequences in Botswana and internationally were made using mutation profiling analysis and phylogenetic inferences. Human samples were not available. A near‐full length SARS‐CoV‐2 genome (∼90% coverage) was successfully genotyped and classified under clade 20 O and Pango‐Lineage AY.43 (Pango v.4.0.6 PLEARN‐v1.3; 2022‐04‐21), which is a sublineage of the Delta variant of concern (VOC) (formerly called B.1.617.2, first detected in India). We did not identify novel mutations that may be used to distinguish SARS‐CoV‐2 isolates from the dog and humans. In addition to Spike (S) region mutation profiling, we performed phylogenetic analysis including 30 Delta sequences publicly available reference also isolated from dogs. In addition, we performed another exploratory analysis to investigate the phylogenetic relatedness of sequence isolated from dog with those from humans in Botswana (n = 1303) as of 31 March 2022 and of same sublineage. Expectedly, the sequence formed a cluster with Delta sublineages – AY.43, AY.116 and B.1.617.2 – circulating in same time frame. This is the first documented report of human‐associated SARS‐CoV‐2 infection in a dog in Botswana. Although the direction of transmission remains unknown, this study further affirms the need for monitoring pets during different COVID‐19 waves for possible clinically relevant SARS‐CoV‐2 transmissions between species.
- Published
- 2023
- Full Text
- View/download PDF
20. Author Correction: Pilot Test of Mopati, a Multi-Level Adherence Intervention for People Living with HIV and Their Treatment Partners in Botswana
- Author
-
Bogart, Laura M., Phaladze, Nthabiseng, Kgotlaetsile, Keonayang, Klein, David J., Goggin, Kathy, and Mosepele, Mosepele
- Published
- 2023
- Full Text
- View/download PDF
21. Cytomegalovirus Immunoglobulin G Levels and Subclinical Arterial Disease among People Living with HIV in Botswana: A Cross-Sectional Study
- Author
-
Thato Moshomo, Onkabetse Julia Molefe-Baikai, Kara Bennett, Tendani Gaolathe, Sikhulile Moyo, Simani Gaseitsewe, Terence Mohammed, Shahin Lockman, and Mosepele Mosepele
- Subjects
cytomegalovirus ,HIV ,cardiovascular ,monocyte activation ,endothelial injury ,Africa ,Biology (General) ,QH301-705.5 - Abstract
Cytomegalovirus (CMV) has been linked with increased cardiovascular risk and monocyte activation in people living with HIV (PLWH). This cross-sectional study aimed to compare CMV immunoglobulin G (IgG) levels between combined antiretroviral therapy (cART)-treated PLWH versus ART-naïve PLWH and those without HIV, and to investigate their associations with biomarkers of endothelial injury and carotid atherosclerosis, in Gaborone, Botswana. All participants were between 30 and 50 years old. Carotid intimal media thickness (cIMT) and biomarkers of endothelial injury and monocyte activation were also assessed. The association between quantitative CMV IgG and cardiovascular disease risk was assessed in multivariate logistic regression analysis. The results showed that the mean CMV IgG level among ART-naïve participants was significantly higher than both the cART group and controls. However, CMV IgG levels did not differ significantly between the controls and cART groups. Among PLWH, CMV IgG levels were associated with ICAM-1 levels and cIMT. Increases in CMV IgG among ART-naïve participants were significantly associated with increases in log VCAM-1. In conclusion, CMV IgG levels are elevated among PLWH in sub-Saharan Africa, and higher levels are associated with biomarkers of endothelial injury and cIMT. Future research should investigate the long-term impact of elevated CMV IgG among PLWH.
- Published
- 2024
- Full Text
- View/download PDF
22. Prevalence of the metabolic syndrome and associated factors among inpatients with severe mental illness in Botswana: a cross-sectional study
- Author
-
Billy M. Tsima, Philip Opondo, Mosepele Mosepele, Emang Mautle, Warren B. Bilker, and Robert Gross
- Subjects
Metabolic syndrome ,Severe mental illness ,Cardiovascular diseases ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Introduction The metabolic syndrome, a cluster of inter-related risk factors for cardiovascular diseases is highly prevalent among individuals with obesity and sedentary lifestyle. Chronic psychiatric disorders such as severe mental illness are associated with increased risk for cardiovascular diseases. We aimed to assess the prevalence and correlates of metabolic syndrome among inpatients with severe mental illness in a resource limited setting with high HIV prevalence. Methods This was a cross-sectional study among adult inpatients at a referral psychiatric hospital in Botswana. We used convenience sampling to enrol participants available at the time of the study. The National Cholesterol Education Program Adult Treatment Panel-III (NCEP-ATP III) criteria was used to define the metabolic syndrome. Data were analysed using descriptive statistics as well as multiple logistic regression modelling. Results A total of 137 participants were enrolled. Of these, 119 (87%) had complete data for the main analysis. The overall prevalence of metabolic syndrome was 22.6% (95% CI 15.9, 30.6) and did not differ significantly by gender or HIV status. Age was significantly associated with the risk of having the metabolic syndrome while gender, body mass index, HIV status, and days of moderate physical activity were not. Conclusion There was a moderately high prevalence of metabolic syndrome. Thus, the management of individuals with severe mental illness in resource limited settings should include assessment of cardiovascular risk and target modifiable risk factors in this population. Consideration for the patient’s age should be made when rationalizing the limited resources available for assessing metabolic syndrome among patients with severe mental illness.
- Published
- 2022
- Full Text
- View/download PDF
23. Economic evaluation of implementation science outcomes in low- and middle-income countries: a scoping review
- Author
-
Akash Malhotra, Ryan R. Thompson, Faith Kagoya, Felix Masiye, Peter Mbewe, Mosepele Mosepele, Jane Phiri, Jairos Sambo, Abigail Barker, Drew B. Cameron, Victor G. Davila-Roman, William Effah, Brian Hutchinson, Michael Laxy, Brad Newsome, David Watkins, Hojoon Sohn, and David W. Dowdy
- Subjects
Economic evaluation ,Implementation science ,Implementation outcomes ,Cost-effectiveness ,Low- and middle-income countries ,Infectious disease ,Medicine (General) ,R5-920 - Abstract
Abstract Background Historically, the focus of cost-effectiveness analyses has been on the costs to operate and deliver interventions after their initial design and launch. The costs related to design and implementation of interventions have often been omitted. Ignoring these costs leads to an underestimation of the true price of interventions and biases economic analyses toward favoring new interventions. This is especially true in low- and middle-income countries (LMICs), where implementation may require substantial up-front investment. This scoping review was conducted to explore the topics, depth, and availability of scientific literature on integrating implementation science into economic evaluations of health interventions in LMICs. Methods We searched Web of Science and PubMed for papers published between January 1, 2010, and December 31, 2021, that included components of both implementation science and economic evaluation. Studies from LMICs were prioritized for review, but papers from high-income countries were included if their methodology/findings were relevant to LMIC settings. Results Six thousand nine hundred eighty-six studies were screened, of which 55 were included in full-text review and 23 selected for inclusion and data extraction. Most papers were theoretical, though some focused on a single disease or disease subset, including: mental health (n = 5), HIV (n = 3), tuberculosis (n = 3), and diabetes (n = 2). Manuscripts included a mix of methodology papers, empirical studies, and other (e.g., narrative) reviews. Authorship of the included literature was skewed toward high-income settings, with 22 of the 23 papers featuring first and senior authors from high-income countries. Of nine empirical studies included, no consistent implementation cost outcomes were measured, and only four could be mapped to an existing costing or implementation framework. There was also substantial heterogeneity across studies in how implementation costs were defined, and the methods used to collect them. Conclusion A sparse but growing literature explores the intersection of implementation science and economic evaluation. Key needs include more research in LMICs, greater consensus on the definition of implementation costs, standardized methods to collect such costs, and identifying outcomes of greatest relevance. Addressing these gaps will result in stronger links between implementation science and economic evaluation and will create more robust and accurate estimates of intervention costs. Trial registration The protocol for this manuscript was published on the Open Science Framework. It is available at: https://osf.io/ms5fa/ (DOI: 10.17605/OSF.IO/32EPJ).
- Published
- 2022
- Full Text
- View/download PDF
24. Public and outpatients’ awareness of calling emergency medical services immediately by acute stroke in an upper middle-income country: a cross-sectional questionnaire study in greater Gaborone, Botswana
- Author
-
Ookeditse Ookeditse, Kebadiretse K. Ookeditse, Thusego R. Motswakadikgwa, Gosiame Masilo, Yaone Bogatsu, Baleufi C. Lekobe, Mosepele Mosepele, Henrik Schirmer, and Stein H. Johnsen
- Subjects
Stroke symptoms ,Stroke risk factors ,Outpatients ,Public ,Awareness ,Emergency medical services ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Highlights • This is the first study comparing awareness of calling EMS among outpatients and public in sub-Saharan Africa • Awareness of calling EMS or seeking immediate medical services by acute stroke was adequate among both outpatients and public • Predictors of low awareness of both calling EMS and seeking immediate medical assistance were no medical insurance, residing/working together, history of psychiatric diseases, and normal weight • Results call for educational campaigns on awareness of calling EMS/ seeking immediate medical assistance by stroke.
- Published
- 2022
- Full Text
- View/download PDF
25. Colonization with extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) and carbapenem-resistant Enterobacterales (CRE) in healthcare and community settings in Botswana: an antibiotic resistance in communities and hospitals (ARCH) study
- Author
-
Naledi Mannathoko, Mosepele Mosepele, Robert Gross, Rachel M. Smith, Kevin Alby, Laurel Glaser, Melissa Richard-Greenblatt, Rebekah Dumm, Aditya Sharma, Anne Jaskowiak-Barr, Leigh Cressman, Kgotlaetsile Sewawa, Laura Cowden, Emily Reesey, Dimpho Otukile, Giacomo M. Paganotti, Margaret Mokomane, and Ebbing Lautenbach
- Subjects
Antibiotic ,Resistance ,Botswana ,Colonization ,Covid ,Infectious and parasitic diseases ,RC109-216 - Abstract
Objectives: Although extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) and carbapenem-resistant Enterobacterales (CRE) are a global challenge, data on these organisms in low- and middle-income countries are limited. In this study, we sought to characterize colonization data critical for greater antibiotic resistance surveillance efforts. Methods: This study was conducted in three hospitals and six clinics in Botswana. We conducted ongoing surveillance of adult patients in hospitals and clinics and adults and children in the community. All participants underwent rectal swab sampling to identify ESCrE and CRE. Results: Enrollment occurred from January 15, 2020, to September 4, 2020, but paused from April 2, 2020, to May 21, 2020, because of a countrywide COVID-19 lockdown. Of 5088 individuals approached, 2469 (49%) participated. ESCrE colonization prevalence was 30.7% overall (43% for hospital participants, 31% for clinic participants, 24% for adult community participants, and 26% for child community participants) (P
- Published
- 2022
- Full Text
- View/download PDF
26. Colonization with extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) in hospitalized patients in Botswana
- Author
-
Naledi Betsi Mannathoko, Mosepele Mosepele, Robert Gross, Rachel Smith, Ashley Styczynski, Leigh Cressman, Melissa Richard-Greenblatt, Laurel Glaser, Kevin Alby, Anne Jaskowiak, Kgotlaetsile Sewawa, Laura Cowden, Dimpho Otukile, Giacomo Paganotti, Margaret Mokomane, Warren Bilker, and Ebbing Lautenbach
- Subjects
Infectious and parasitic diseases ,RC109-216 ,Public aspects of medicine ,RA1-1270 - Abstract
Background: The epidemiology of extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) in hospitalized patients in low- and middle-income countries (LMICs) is poorly described. Although risk factors for ESCrE clinical infection have been studied, little is known of the epidemiology of ESCrE colonization. Identifying risk factors for ESCrE colonization, which can predispose to infection, is therefore critical to inform antibiotic resistance reduction strategies. Methods: This study was conducted in 3 hospitals located in 3 districts in Botswana. In each hospital, we conducted ongoing surveillance in sequential units hospitalwide. All participants had rectal swabs collected which were inoculated onto chromogenic media followed by confirmatory testing using MALDI-TOF MS and VITEK-2. Data were collected via interview and review of the inpatient medical record on demographics, comorbidities, antibiotic use, healthcare exposures, invasive procedures, travel, animal contact, and food consumption. Participants with ESCrE colonization (cases) were compared to noncolonized participants (controls) using bivariable and multivariable analyses to identify risk factors for ESCrE colonization. Results: Enrollment occurred from January 15, 2020, to September 4, 2020, and 469 participants were enrolled. The median age was 42 years (IQR, 31–58) and 320 (68.2%) were female. The median time from hospital admission to date of sampling was 5 days (IQR, 3–12). There were 179 cases and 290 controls (ie, 38.2% of participants were ESCrE colonized). Independent risk factors for ESCrE colonization were a greater number of days on antibiotic, recent healthcare exposure, and tending swine prior to hospitalization. (Table). Conclusions: ESCrE colonization among hospitalized patients was common and was associated with several exposures. Our results suggest prior healthcare exposure may be important in driving ESCrE. The strong link to recent antibiotic use highlights the potential role of antibiotic stewardship interventions for prevention. The association with tending swine suggests that animal husbandry practices may play a role in community exposures, resulting in colonization detected at the time of hospital admission. These findings will help to inform future studies assessing strategies to curb further emergence of hospital ESCrE in LMICs.
- Published
- 2023
- Full Text
- View/download PDF
27. Poor sleep quality is linked to increased frailty in middle-aged people living with HIV in Botswana
- Author
-
Zheng, Xi, primary, Cai, Ruixue, additional, Gao, Chenlu, additional, Ponatshego, Ponego, additional, Gao, Lei, additional, Montano, Monty A., additional, Hu, Kun, additional, Mosepele, Mosepele, additional, and Li, Peng, additional
- Published
- 2024
- Full Text
- View/download PDF
28. Molecular Characterization of Hepatitis B Virus in People Living With HIV in Rural and Peri-Urban Communities in Botswana
- Author
-
Phinius, Bonolo B., primary, Choga, Wonderful T., additional, Anderson, Motswedi, additional, Mokomane, Margaret, additional, Gobe, Irene, additional, Ratsoma, Tsholofelo, additional, Phakedi, Basetsana, additional, Mpebe, Gorata, additional, Bhebhe, Lynnette, additional, Gaolathe, Tendani, additional, Mosepele, Mosepele, additional, Makhema, Joseph, additional, Shapiro, Roger, additional, Lockman, Shahin, additional, Musonda, Rosemary, additional, Moyo, Sikhulile, additional, and Gaseitsiwe, Simani, additional
- Published
- 2024
- Full Text
- View/download PDF
29. Role of Support Reciprocity in HIV Viral Suppression Among People Living with HIV and Their Treatment Partners in Botswana
- Author
-
Bogart, Laura M., Phaladze, Nthabiseng, Green, Harold D., Klein, David J., Kgotlaetsile, Keonayang, Lekoko, Bright, and Mosepele, Mosepele
- Published
- 2022
- Full Text
- View/download PDF
30. Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial
- Author
-
Goodall, Jack, Lechiile, Kwana, Mawoko, Norah, Mbangiwa, Tshepiso, Milburn, James, Mmipi, Refilwe, Ponatshego, Ponego, Rulaganyang, Ikanyang, Seatla, Kaelo, Siamisang, Keatlaretse, Tlhako, Nametso, Tsholo, Katlego, April, Samantha, Bekiswa, Abulele, Boloko, Linda, Bookholane, Hloni, Crede, Thomas, Davids, Lee-Ann, Goliath, Rene, Hlungulu, Siphokazi, Hoffman, Regina, Kyepa, Henriette, Masina, Noma, Maughan, Deborah, Mnguni, Trevor, Moosa, Sumaiyya, Morar, Tania, Mpalali, Mkanyiseli, Naude, Jonathan, Oliphant, Ida, Singh, Achita, Sayed, Sumaya, Sebesho, Leago, Shey, Muki, Swanepoel, Loraine, Chasweka, Madalitso, Chimang'anga, Wezi, Chimphambano, Tipatseni, Gondwe, Ebbie, Mzinganjira, Henry, Kadzilimbile, Aubrey, Kateta, Steven, Kossam, Evelyn, Kukacha, Christopher, Lipenga, Bright, Ndaferankhande, John, Ndalama, Maureen, Shah, Reya, Singini, Andreas, Stott, Katherine, Zambasa, Agness, Banda, Towera, Chikaonda, Tarsizio, Chitulo, Gladys, Chiwoko, Lorren, Chome, Nelecy, Gwin, Mary, Kachitosi, Timothy, Kamanga, Beauty, Kazembe, Mussah, Kumwenda, Emily, Kumwenda, Masida, Maya, Chimwemwe, Mhango, Wilberforce, Mphande, Chimwemwe, Msumba, Lusungu, Munthali, Tapiwa, Ngoma, Doris, Nicholas, Simon, Simwinga, Lusayo, Stambuli, Anthony, Tegha, Gerald, Zambezi, Janet, Ahimbisibwe, Cynthia, Akampurira, Andrew, Alice, Anamudde, Cresswell, Fiona, Gakuru, Jane, Kagimu, Enock, Kasibante, John, Kiiza, Daniel, Kisembo, John, Kwizera, Richard, Kugonza, Florence, Laker, Eva, Luggya, Tonny, Lule, Andrew, Musubire, Abdu, Muyise, Rhona, Namujju, Carol Olivie, Ndyetukira, Jane Francis, Nsangi, Laura, Okirworth, Michael, Rhein, Joshua, Rutakingirwa, Morris K, Sadiq, Alisat, Ssebambulidde, Kenneth, Tadeo, Kiiza, Tukundane, Asmus, Atwine, Leo, Buzaare, Peter, Collins, Muganzi, Emily, Ninsima, Inyakuwa, Christine, Kariisa, Samson, Mwesigye, James, Nuwamanya, Simpson, Rodgers, Ankunda, Rukundo, Joan, Rwomushana, Irene, Ssemusu, Mike, Stead, Gavin, Boyd, Kathyrn, Gondo, Secrecy, Kufa, Prosper, Makaha, Edward, Moyo, Colombus, Mtisi, Takudzwa, Mudzinga, Shepherd, Mutata, Constantine, Mwarumba, Taddy, Zinyandu, Tawanda, Alanio, Alexandre, Dromer, Francoise, Lortholary, Olivier, Sturny-Leclere, Aude, Griffin, Philippa, Hafeez, Sophia, Loyse, Angela, van Widenfelt, Erik, Lawrence, David S, Muthoga, Charles, Meya, David B, Tugume, Lillian, Williams, Darlisha, Rajasingham, Radha, Boulware, David R, Mwandumba, Henry C, Moyo, Melanie, Dziwani, Eltas N, Maheswaran, Hendramoorthy, Kanyama, Cecilia, Hosseinipour, Mina C, Chawinga, Chimwemwe, Meintjes, Graeme, Schutz, Charlotte, Comins, Kyla, Bango, Funeka, Muzoora, Conrad, Jjunju, Samuel, Nuwagira, Edwin, Mosepele, Mosepele, Leeme, Tshepo, Ndhlovu, Chiratidzo E, Hlupeni, Admire, Shamu, Shepherd, Boyer-Chammard, Timothée, Molloy, Síle F, Youssouf, Nabila, Chen, Tao, Shiri, Tinevimbo, Jaffar, Shabbar, Harrison, Thomas S, Jarvis, Joseph N, and Niessen, Louis W
- Published
- 2022
- Full Text
- View/download PDF
31. Colonization with extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) and carbapenem-resistant Enterobacterales (CRE) in healthcare and community settings in Botswana: an antibiotic resistance in communities and hospitals (ARCH) study
- Author
-
Mannathoko, Naledi, Mosepele, Mosepele, Gross, Robert, Smith, Rachel M., Alby, Kevin, Glaser, Laurel, Richard-Greenblatt, Melissa, Dumm, Rebekah, Sharma, Aditya, Jaskowiak-Barr, Anne, Cressman, Leigh, Sewawa, Kgotlaetsile, Cowden, Laura, Reesey, Emily, Otukile, Dimpho, Paganotti, Giacomo M., Mokomane, Margaret, and Lautenbach, Ebbing
- Published
- 2022
- Full Text
- View/download PDF
32. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
- Author
-
Viana, Raquel, Moyo, Sikhulile, Amoako, Daniel G., Tegally, Houriiyah, Scheepers, Cathrine, Althaus, Christian L., Anyaneji, Ugochukwu J., Bester, Phillip A., Boni, Maciej F., Chand, Mohammed, Choga, Wonderful T., Colquhoun, Rachel, Davids, Michaela, Deforche, Koen, Doolabh, Deelan, du Plessis, Louis, Engelbrecht, Susan, Everatt, Josie, Giandhari, Jennifer, Giovanetti, Marta, Hardie, Diana, Hill, Verity, Hsiao, Nei-Yuan, Iranzadeh, Arash, Ismail, Arshad, Joseph, Charity, Joseph, Rageema, Koopile, Legodile, Kosakovsky Pond, Sergei L., Kraemer, Moritz U. G., Kuate-Lere, Lesego, Laguda-Akingba, Oluwakemi, Lesetedi-Mafoko, Onalethatha, Lessells, Richard J., Lockman, Shahin, Lucaci, Alexander G., Maharaj, Arisha, Mahlangu, Boitshoko, Maponga, Tongai, Mahlakwane, Kamela, Makatini, Zinhle, Marais, Gert, Maruapula, Dorcas, Masupu, Kereng, Matshaba, Mogomotsi, Mayaphi, Simnikiwe, Mbhele, Nokuzola, Mbulawa, Mpaphi B., Mendes, Adriano, Mlisana, Koleka, Mnguni, Anele, Mohale, Thabo, Moir, Monika, Moruisi, Kgomotso, Mosepele, Mosepele, Motsatsi, Gerald, Motswaledi, Modisa S., Mphoyakgosi, Thongbotho, Msomi, Nokukhanya, Mwangi, Peter N., Naidoo, Yeshnee, Ntuli, Noxolo, Nyaga, Martin, Olubayo, Lucier, Pillay, Sureshnee, Radibe, Botshelo, Ramphal, Yajna, Ramphal, Upasana, San, James E., Scott, Lesley, Shapiro, Roger, Singh, Lavanya, Smith-Lawrence, Pamela, Stevens, Wendy, Strydom, Amy, Subramoney, Kathleen, Tebeila, Naume, Tshiabuila, Derek, Tsui, Joseph, van Wyk, Stephanie, Weaver, Steven, Wibmer, Constantinos K., Wilkinson, Eduan, Wolter, Nicole, Zarebski, Alexander E., Zuze, Boitumelo, Goedhals, Dominique, Preiser, Wolfgang, Treurnicht, Florette, Venter, Marietje, Williamson, Carolyn, Pybus, Oliver G., Bhiman, Jinal, Glass, Allison, Martin, Darren P., Rambaut, Andrew, Gaseitsiwe, Simani, von Gottberg, Anne, and de Oliveira, Tulio
- Published
- 2022
- Full Text
- View/download PDF
33. Economic evaluation of implementation science outcomes in low- and middle-income countries: a scoping review
- Author
-
Malhotra, Akash, Thompson, Ryan R., Kagoya, Faith, Masiye, Felix, Mbewe, Peter, Mosepele, Mosepele, Phiri, Jane, Sambo, Jairos, Barker, Abigail, Cameron, Drew B., Davila-Roman, Victor G., Effah, William, Hutchinson, Brian, Laxy, Michael, Newsome, Brad, Watkins, David, Sohn, Hojoon, and Dowdy, David W.
- Published
- 2022
- Full Text
- View/download PDF
34. Prevalence of the metabolic syndrome and associated factors among inpatients with severe mental illness in Botswana: a cross-sectional study
- Author
-
Tsima, Billy M., Opondo, Philip, Mosepele, Mosepele, Mautle, Emang, Bilker, Warren B., and Gross, Robert
- Published
- 2022
- Full Text
- View/download PDF
35. Qualitative Evaluation of Treatment Partners for People With HIV in Botswana: Current Healthcare Provider Practices and Recommendations for Improvement.
- Author
-
Bogart, Laura M., Phaladze, Nthabiseng, Kgotlaetsile, Keonayang, Goggin, Kathy, and Mosepele, Mosepele
- Subjects
HIV infection epidemiology ,PATIENT compliance ,ANTIRETROVIRAL agents ,RESEARCH funding ,QUALITATIVE research ,FOCUS groups ,MEDICAL quality control ,STATISTICAL sampling ,QUESTIONNAIRES ,HIV infections ,SERVICES for caregivers ,PSYCHOLOGY of HIV-positive persons ,CAREGIVERS ,THEMATIC analysis ,PSYCHOLOGY of caregivers ,QUALITY assurance ,SOCIAL support ,DRUGS ,INTER-observer reliability - Abstract
Botswana has an adult HIV prevalence of 20.8% and annual incidence of 0.2%. We aimed to evaluate current practices and advance recommendations for treatment partners (informal adherence supporters) for people with HIV in Botswana. In January-February 2020, we conducted seven focus groups with 36 healthcare providers at seven HIV clinics in Gaborone, Botswana. Providers perceived treatment partners to be critical for quality patient care. They shared that in the new era of universal antiretroviral therapy (ART) initiation immediately after diagnosis ("test-and-treat"), providers no longer require patients to select treatment partners at ART initiation. Providers suggested a renewed emphasis on treatment partners. They believed that standard guidance for providers around treatment partner selection would ensure that providers cover similar topics across patients and endorsed implementation of workshops to educate treatment partners on how to support patients. However, streamlined ART initiation policies require innovative strategies, including eHealth interventions, to engage treatment partners. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. No impact of COVID-19 at delivery on maternal mortality or infant adverse birth outcomes in Botswana during the Omicron era.
- Author
-
Banga, Jaspreet, Jackson-Gibson, Maya, Diseko, Modiegi, Caniglia, Ellen C., Mayondi, Gloria, Mabuta, Judith, Luckett, Rebecca, Moyo, Sikhulile, Smith-Lawrence, Pamela, Mosepele, Mosepele, Lockman, Shahin, Makhema, Joseph, Zash, Rebecca, and Shapiro, Roger
- Subjects
SARS-CoV-2 Omicron variant ,MATERNAL mortality ,ANTIGEN analysis ,DIAGNOSTIC use of polymerase chain reaction ,HERD immunity - Abstract
SARS-CoV-2 infection during pregnancy was associated with maternal mortality and adverse birth outcomes in the pre-Omicron era, including a stillbirth rate of 5.6% in Botswana. We re-evaluated these outcomes in the Tsepamo Study during the Omicron era. We assessed maternal mortality and adverse birth outcomes for all singleton pregnancies from mid-November 2021 (the start of the Omicron era) to mid-August 2022 at nine Tsepamo sites, among individuals with documented SARS-CoV-2 screening PCR or antigen tests and known HIV status. Of 9,705 women routinely screened for SARS-CoV-2 infection at delivery (64% of deliveries at these sites), 373 (3.8%) tested positive. Women with HIV were as likely to test positive for SARS-CoV-2 (77/1833, 4.2%) as women without HIV (293/6981, 4.2%) (p = 1.0). There were 5 recorded maternal deaths (0.03%), one occurring in a woman with a positive SARS-CoV-2 test result. In contrast, maternal mortality was 3.7% and 0.1% in those with and without SARS-CoV-2, respectively, during the pre-Omicron era. In the Omicron era, there were no differences among infants exposed or unexposed to SARS-CoV-2 in overall adverse birth outcomes (28.1% vs 29.6%; aRR 1.0, 95%CI 0.8–1.1), severe adverse birth outcomes (11.9 vs 10.6%; aRR 1.1, 95%CI 0.8–1.5), preterm delivery (15.1% vs 14.9%; aRR 1.0, 95%CI 0.8–1.3), or stillbirth (1.9% vs 2.3%; aRR 0.8, 95%CI 0.4–1.7). Adverse outcomes among those exposed to both HIV and SARS-CoV-2 were similar to those exposed to HIV alone (31.2% vs. 33.1%; aRR 0.9, 95%CI 0.6–1.3; p = 0.5). Maternal mortality was far lower in Botswana during the Omicron era than in the pre-Omicron era, and adverse birth outcomes were no longer significantly impacted by exposure to SARS-CoV-2 either overall or with HIV co-exposure. Increased population immunity to SARS-CoV-2, less stress on the hospital systems in the Omicron era, and possible differences in viral pathogenicity may combine to explain these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Maternal biomarkers of endothelial dysfunction and pregnancy outcomes in women with and without HIV in Botswana.
- Author
-
Gaerolwe Masheto, Sikhulile Moyo, Terence Mohammed, Christine Banda, Charlene Raphaka, Gloria Mayondi, Joseph Makhema, Roger Shapiro, Mosepele Mosepele, Rebecca Zash, and Shahin Lockman
- Subjects
Medicine ,Science - Abstract
BackgroundWomen living with HIV-1 (WLHIV) are at higher risk of having an adverse birth outcome, but the underlying mechanism(s) are unknown. We hypothesized that HIV-associated endothelial activation could adversely impact placental function and lead to impaired fetal growth or stillbirth.MethodsWe used stored samples from WLHIV and HIV-negative women who had enrolled during pregnancy in the observational Botswana Tshipidi cohort. Written informed consent was obtained from the participants. We measured plasma levels of markers of endothelial activation (soluble vascular adhesion molecule 1 [VCAM-1], intercellular adhesion molecule 1 [ICAM-1] and E-selectin) from samples taken during pregnancy. We compared log10 biomarker levels by maternal HIV status and by the timing of ART initiation (ART prior to conception vs. during pregnancy; ART prior to sample collection vs. no ART prior to sampling) using t-tests and the Kruskal-Wallis rank test. We evaluated the association between these biomarkers and adverse birth outcomes (composite of stillbirth or small for gestational age [SGA]) using univariate and multivariate log-binomial regression controlling for maternal age (continuous) and timing of ART start. We also used generalized linear models (GLM) to evaluate the association between continuous birthweight (in grams) and gestational age (in weeks) and markers of endothelial dysfunction, adjusting for maternal age (continuous) and timing of ART relative to sample collection.ResultsSpecimens collected before delivery were available for 414 women (372 WLHIV and 42 HIV-negative women), with a median age of 28 years and median gestational age at sample collection of 30 weeks (range 26, 35 weeks). WLHIV had significantly higher median VCAM1 (p = 0.002) than HIV-negative women, but HIV-negative women had higher median ICAM1 (p = 0.01); e-Selectin levels did not differ by maternal HIV status. Women starting ART during pregnancy had higher log10 VCAM1 levels than those on ART before conception, regardless of whether the sample was collected before (p = 0.02) or after (p = 0.03) ART initiation. However, ICAM1 and e-Selectin did not differ significantly by ART status or ART timing. Ninety-eight women (91 WLHIV and 7 HIV-negative), or 9 (2%) and 89 (22%) included in this study, had a stillborn or SGA baby respectively. Univariate and adjusted analyses did not show significant associations between levels of any of the biomarkers with these adverse birth outcomes. However, lower birthweight (p = 0.03) and lower gestational age at delivery were associated e-Selectin and ICAM (p = 0.008), respectively.ConclusionMaternal HIV infection and lack of ART (or recent ART initiation) were associated with one marker of greater endothelial activation (VCAM-1), but not with other markers (ICAM-1 nor E-selectin) in pregnancy. e-Selectin was associated with lower birthweight and every unit increase in log ICAM-1 at delivery was associated with lower gestation age at delivery.
- Published
- 2023
- Full Text
- View/download PDF
38. Healthcare professionals' knowledge of modifiable stroke risk factors: A cross-sectional questionnaire survey in greater Gaborone, Botswana
- Author
-
Ookeditse, Ookeditse, Motswakadikgwa, Thusego R., Ookeditse, Kebadiretse K., Masilo, Gosiame, Bogatsu, Yaone, Lekobe, Baleufi C., Mosepele, Mosepele, Schirmer, Henrik, and Johnsen, Stein H.
- Published
- 2021
- Full Text
- View/download PDF
39. Cytomegalovirus Immunoglobulin G Levels and Subclinical Arterial Disease among People Living with HIV in Botswana: A Cross-Sectional Study
- Author
-
Moshomo, Thato, primary, Molefe-Baikai, Onkabetse Julia, additional, Bennett, Kara, additional, Gaolathe, Tendani, additional, Moyo, Sikhulile, additional, Gaseitsewe, Simani, additional, Mohammed, Terence, additional, Lockman, Shahin, additional, and Mosepele, Mosepele, additional
- Published
- 2024
- Full Text
- View/download PDF
40. Development and validation of quantitative PCR assays for HIV-associated cryptococcal meningitis in sub-Saharan Africa: a diagnostic accuracy study
- Author
-
Mbangiwa, Tshepiso, primary, Sturny-Leclère, Aude, additional, Lechiile, Kwana, additional, Kajanga, Cheusisime, additional, Boyer-Chammard, Timothée, additional, Hoving, Jennifer C, additional, Leeme, Tshepo, additional, Moyo, Melanie, additional, Youssouf, Nabila, additional, Lawrence, David S, additional, Mwandumba, Henry, additional, Mosepele, Mosepele, additional, Harrison, Thomas S, additional, Jarvis, Joseph N, additional, Lortholary, Olivier, additional, Alanio, Alexandre, additional, Goodall, J, additional, Mawoko, N, additional, Milburn, J, additional, Mmipi, R, additional, Muthoga, C, additional, Ponatshego, P, additional, Rulaganyang, I, additional, Seatla, K, additional, Tlhako, N, additional, Tsholo, K, additional, April, S, additional, Bekiswa, A, additional, Boloko, L, additional, Bookholane, H, additional, Crede, T, additional, Davids, L, additional, Goliath, R, additional, Hlungulu, S, additional, Hoffman, R, additional, Kyepa, H, additional, Masina, N, additional, Maughan, D, additional, Mnguni, T, additional, Moosa, S, additional, Morar, T, additional, Mpalali, M, additional, Naude, J, additional, Oliphant, I, additional, Sayed, S, additional, Sebesho, L, additional, Shey, M, additional, Swanepoel, L, additional, Chasweka, M, additional, Chimang’anga, W, additional, Chimphambano, T, additional, Dziwani, E, additional, Gondwe, E, additional, Kadzilimbile, A, additional, Kateta, S, additional, Kossam, E, additional, Kukacha, C, additional, Lipenga, B, additional, Ndaferankhande, J, additional, Ndalama, M, additional, Shah, R, additional, Singini, A, additional, Stott, K, additional, Zambasa, A, additional, Banda, T, additional, Chikaonda, T, additional, Chitulo, G, additional, Chiwoko, L, additional, Chome, N, additional, Gwin, M, additional, Kachitosi, T, additional, Kamanga, B, additional, Kazembe, M, additional, Kumwenda, E, additional, Kumwenda, M, additional, Maya, C, additional, Mhango, W, additional, Mphande, C, additional, Msumba, L, additional, Munthali, T, additional, Ngoma, D, additional, Nicholas, S, additional, Simwinga, L, additional, Stambuli, A, additional, Tegha, G, additional, Zambezi, J, additional, Ahimbisibwe, C, additional, Akampurira, A, additional, Alice, A, additional, Cresswell, F, additional, Gakuru, J, additional, Kiiza, D, additional, Kisembo, J, additional, Kwizera, R, additional, Kugonza, F, additional, Laker, E, additional, Luggya, T, additional, Lule, A, additional, Musubire, A, additional, Muyise, R, additional, Namujju, O, additional, Ndyetukira, J, additional, Nsangi, L, additional, Okirwoth, M, additional, Sadiq, A, additional, Tadeo, K, additional, Tukundane, A, additional, Williams, D, additional, Atwine, L, additional, Buzaare, P, additional, Collins, M, additional, Emily, N, additional, Inyakuwa, C, additional, Kariisa, S, additional, Mwesigye, J, additional, Niwamanya, S, additional, Rodgers, A, additional, Rukundo, J, additional, Rwomushana, I, additional, Ssemusu, M, additional, Stead, G, additional, Boyd, K, additional, Gondo, S, additional, Kufa, P, additional, Makaha, E, additional, Moyo, C, additional, Mtisi, T, additional, Mudzingwa, S, additional, Mwarumba, T, additional, Zinyandu, T, additional, Dromer, F, additional, Johnstone, P, additional, and Hafeez, S, additional
- Published
- 2024
- Full Text
- View/download PDF
41. Low Prevalence of Nirmatrelvir-Ritonavir Resistance-Associated Mutations in SARS-CoV-2 Lineages From Botswana.
- Author
-
Choga, Wonderful T, Bareng, Ontlametse T, Moraka, Natasha O, Maruapula, Dorcas, Gobe, Irene, Ndlovu, Nokuthula S, Zuze, Boitumelo J L, Motshosi, Patience C, Seru, Kedumetse B, Matsuru, Teko, Boitswarelo, Matshwenyego, Matshaba, Mogomotsi, Gaolathe, Tendani, Mosepele, Mosepele, Makhema, Joseph, Tamura, Trevor J M, Li, Jonathan Z, Shapiro, Roger, Lockman, Shahin, and Gaseitsiwe, Simani
- Subjects
SARS-CoV-2 ,COVID-19 ,SARS-CoV-2 Omicron variant ,COVID-19 treatment ,GENETIC polymorphisms - Abstract
Background We evaluated naturally occurring nirmatrelvir-ritonavir (NTV/r) resistance-associated mutations (RAMs) among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains from Botswana, a country with no NTV/r use to date, in order to recommend the usage of the agent for high-risk patients with coronavirus disease 2019 (COVID-19). Methods We conducted a retrospective analysis using 5254 complete SARS-CoV-2 sequences from Botswana (September 2020–September 2023). We evaluated the mutational landscape of SARS-CoV-2 3-Chymotrypsin-like protease (3CLpro) relative to the highlighted list of RAMs granted Food and Drug Administration Emergency Use Authorization in 2023. Results The sequenced 5254 samples included Beta variants of concerns (VOCs; n = 323), Delta VOCs (n = 1314), and Omicron VOCs (n = 3354). Overall, 77.8% of the sequences exhibited at least 1 polymorphism within 76/306 amino acid positions in the nsp5 gene. NTV/rRAMs were identified in 34/5254 (0.65%; 95% CI, 0.43%–0.87%) and occurred at 5 distinct positions. Among the NTV/r RAMS detected, A191V was the most prevalent (24/34; 70.6%). Notably, T21I mutation had a prevalence of 20.6% (7/34) and coexisted with either K90R (n = 3) polymorphism in Beta sequences with RAMs or P132H (n = 3) polymorphism for Omicron sequences with RAMs. Other NTV/r RAMs detected included P108S, with a prevalence of 5.88% (2/34), and L50F, with a prevalence of 2.94% (1/34). NTV/r RAMs were significantly higher (P <.001) in Delta (24/35) compared with Beta (4/34) and Omicron (6/34) sequences. Conclusions The frequency of NTV/r RAMs in Botswana was low. Higher rates were observed in Delta VOCs compared to Omicron and Beta VOCs. As NTV/r use expands globally, continuous surveillance for drug-resistant variants is essential, given the RAMs identified in our study. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Molecular Characterization of Hepatitis B Virus in People Living with HIV in Rural and Peri-Urban Communities in Botswana.
- Author
-
Phinius, Bonolo B., Choga, Wonderful T., Anderson, Motswedi, Mokomane, Margaret, Gobe, Irene, Ratsoma, Tsholofelo, Phakedi, Basetsana, Mpebe, Gorata, Bhebhe, Lynnette, Gaolathe, Tendani, Mosepele, Mosepele, Makhema, Joseph, Shapiro, Roger, Lockman, Shahin, Musonda, Rosemary, Moyo, Sikhulile, and Gaseitsiwe, Simani
- Subjects
HEPATITIS B virus ,HIV ,HIV-positive persons ,HEPATITIS B ,DNA sequencing - Abstract
(1) Background: Hepatitis B virus (HBV) sequencing data are important for monitoring HBV evolution. We aimed to molecularly characterize HBV sequences from participants with HBV surface antigen-positive (HBsAg+) serology and occult hepatitis B infection (OBI+). (2) Methods: We utilized archived plasma samples from people living with human immunodeficiency virus (PLWH) in Botswana. HBV DNA was sequenced, genotyped and analyzed for mutations. We compared mutations from study sequences to those from previously generated HBV sequences in Botswana. The impact of OBI-associated mutations on protein function was assessed using the Protein Variation Effect Analyzer. (3) Results: Sequencing success was higher in HBsAg+ than in OBI+ samples [86/128 (67.2%) vs. 21/71 (29.2%)]. Overall, 93.5% (100/107) of sequences were genotype A1, 2.8% (3/107) were D3 and 3.7% (4/107) were E. We identified 13 escape mutations in 18/90 (20%) sequences with HBsAg coverage, with K122R having the highest frequency. The mutational profile of current sequences differed from previous Botswana HBV sequences, suggesting possible mutational changes over time. Mutations deemed to have an impact on protein function were
tp Q6H,surface V194A andpreC W28L. (4) Conclusions: We characterized HBV sequences from PLWH in Botswana. Escape mutations were prevalent and were not associated with OBI. Longitudinal HBV studies are needed to investigate HBV natural evolution. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
43. Feasibility and acceptability of HIV self-testing for men of middle-to-upper socio-economic status in Botswana: a pilot study at four (4) worksites in the financial sector
- Author
-
Kgotlaetsile, Keonayang, primary, Bogart, Laura M, additional, Phaladze, Nthabiseng, additional, Klein, David J, additional, and Mosepele, Mosepele, additional
- Published
- 2023
- Full Text
- View/download PDF
44. PA-390 Evaluation of the Saline Gargle collection method for the molecular detection and sequencing of SARS-CoV-2 in Botswana
- Author
-
Lechiile, Kwana, primary, Mokomane, Margaret, additional, Kinshella, Maggie Woo, additional, Bagatiseng, Gofaone, additional, Kayda, Iryna, additional, Gaseitsiwe, Simani, additional, Strysko, Jonathan, additional, Mosepele, Mosepele, additional, Moyo, Sikhulile, additional, Choga, Wonderful, additional, and Goldfarb, David M, additional
- Published
- 2023
- Full Text
- View/download PDF
45. Performance of CHROMagar ESBL media for the surveillance of extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) from rectal swabs in Botswana
- Author
-
Mannathoko, Naledi, primary, Lautenbach, Ebbing, additional, Mosepele, Mosepele, additional, Otukile, Dimpho, additional, Sewawa, Kgotlaetsile, additional, Glaser, Laurel, additional, Cressman, Leigh, additional, Cowden, Laura, additional, Alby, Kevin, additional, Jaskowiak-Barr, Anne, additional, Gross, Robert, additional, Mokomane, Margaret, additional, Paganotti, Giacomo M., additional, Styczynski, Ashley, additional, Smith, Rachel M., additional, Snitkin, Evan, additional, Wan, Tiffany, additional, Bilker, Warren B., additional, and Richard-Greenblatt, Melissa, additional
- Published
- 2023
- Full Text
- View/download PDF
46. Equity in clinical trials for HIV-associated cryptococcal meningitis: A systematic review of global representation and inclusion of patients and researchers.
- Author
-
David S Lawrence, Tshepo Leeme, Mosepele Mosepele, Thomas S Harrison, Janet Seeley, and Joseph N Jarvis
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundIt is essential that clinical trial participants are representative of the population under investigation. Using HIV-associated cryptococcal meningitis (CM) as a case study, we conducted a systematic review of clinical trials to determine how inclusive and representative they were both in terms of the affected population and the involvement of local investigators.MethodsWe searched Medline, EMBASE, Cochrane, Africa-Wide, CINAHL Plus, and Web of Science. Data were extracted for 5 domains: study location and design, screening, participants, researchers, and funders. Data were summarised and compared over 3 time periods: pre-antiretroviral therapy (ART) (pre-2000), early ART (2000 to 2009), and established ART (post-2010) using chi-squared and chi-squared for trend. Comparisons were made with global disease burden estimates and a composite reference derived from observational studies.ResultsThirty-nine trials published between 1990 and 2019 were included. Earlier studies were predominantly conducted in high-income countries (HICs) and recent studies in low- and middle-income countries (LMICs). Most recent studies occurred in high CM incidence countries, but some highly affected countries have not hosted trials. The sex and ART status of participants matched those of the general CM population. Patients with reduced consciousness and those suffering a CM relapse were underrepresented. Authorship had poor representation of women (29% of all authors), particularly as first and final authors. Compared to trials conducted in HICs, trials conducted in LMICs were more likely to include female authors (32% versus 20% p = 0.014) but less likely to have authors resident in (75% versus 100%, p < 0.001) or nationals (61% versus 93%, p < 0.001) of the trial location.ConclusionsThere has been a marked shift in CM trials over the course of the HIV epidemic. Trials are primarily performed in locations and populations that reflect the burden of disease, but severe and relapse cases are underrepresented. Most CM trials now take place in LMICs, but the research is primarily funded and led by individuals and institutions from HICs.
- Published
- 2021
- Full Text
- View/download PDF
47. Reversal of CSF HIV-1 Escape during Treatment of HIV-Associated Cryptococcal Meningitis in Botswana
- Author
-
Nametso Kelentse, Sikhulile Moyo, Kesaobaka Molebatsi, Olorato Morerinyane, Shatho Bitsang, Ontlametse T. Bareng, Kwana Lechiile, Tshepo B. Leeme, David S. Lawrence, Ishmael Kasvosve, Rosemary Musonda, Mosepele Mosepele, Thomas S. Harrison, Joseph N. Jarvis, and Simani Gaseitsiwe
- Subjects
HIV ,cryptococcal meningitis ,HIV-1 viral load ,cerebrospinal fluid (CSF) viral escape ,Botswana ,Biology (General) ,QH301-705.5 - Abstract
Cerebrospinal fluid (CSF) viral escape has been poorly described among people with HIV-associated cryptococcal meningitis. We determined the prevalence of CSF viral escape and HIV-1 viral load (VL) trajectories in individuals treated for HIV-associated cryptococcal meningitis. A retrospective longitudinal study was performed using paired CSF and plasma collected prior to and during the antifungal treatment of 83 participants recruited at the Botswana site of the phase-3 AMBITION-cm trial (2018–2021). HIV-1 RNA levels were quantified then CSF viral escape (CSF HIV-1 RNA ≥ 0.5 log10 higher than plasma) and HIV-1 VL trajectories were assessed. CSF viral escape occurred in 20/62 (32.3%; 95% confidence interval [CI]: 21.9–44.6%), 13/52 (25.0%; 95% CI: 15.2–38.2%) and 1/33 (3.0%; 95% CI: 0.16–15.3%) participants at days 1, 7 and 14 respectively. CSF viral escape was significantly lower on day 14 compared to days 1 and 7, p = 0.003 and p = 0.02, respectively. HIV-1 VL decreased significantly from day 1 to day 14 post antifungal therapy in the CSF but not in the plasma (β = −0.47; 95% CI: −0.69 to −0.25; p < 0.001). CSF viral escape is high among individuals presenting with HIV-associated cryptococcal meningitis; however, antifungal therapy may reverse this, highlighting the importance of rapid initiation of antifungal therapy in these patients.
- Published
- 2022
- Full Text
- View/download PDF
48. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
- Author
-
David S. Lawrence, Nabila Youssouf, Síle F. Molloy, Alexandre Alanio, Melanie Alufandika, David R. Boulware, Timothée Boyer-Chammard, Tao Chen, Francoise Dromer, Admire Hlupeni, William Hope, Mina C. Hosseinipour, Cecilia Kanyama, Oliver Lortholary, Angela Loyse, David B. Meya, Mosepele Mosepele, Conrad Muzoora, Henry C. Mwandumba, Chiratidzo E. Ndhlovu, Louis Niessen, Charlotte Schutz, Katharine E. Stott, Duolao Wang, David G. Lalloo, Graeme Meintjes, Shabbar Jaffar, Thomas S. Harrison, and Joseph N. Jarvis
- Subjects
Cryptococcal meningitis ,HIV ,AmBisome ,Amphotericin B ,Fluconazole ,Flucytosine ,Medicine (General) ,R5-920 - Abstract
Abstract Background Cryptococcal meningitis (CM) is a major cause of mortality in HIV programmes in Africa despite increasing access to antiretroviral therapy (ART). Mortality is driven in part by limited availability of amphotericin-based treatment, drug-induced toxicities of amphotericin B deoxycholate and prolonged hospital admissions. A single, high-dose of liposomal amphotericin (L-AmB, Ambisome) on a fluconazole backbone has been reported as non-inferior to 14 days of standard dose L-AmB in reducing fungal burden. This trial examines whether single, high-dose L-AmB given with high-dose fluconazole and flucytosine is non-inferior to a seven-day course of amphotericin B deoxycholate plus flucytosine (the current World Health Organization [WHO] recommended treatment regimen). Methods An open-label phase III randomised controlled non-inferiority trial conducted in five countries in sub-Saharan Africa: Botswana, Malawi, South Africa, Uganda and Zimbabwe. The trial will compare CM induction therapy with (1) a single dose (10 mg/kg) of L-AmB given with 14 days of fluconazole (1200 mg/day) and flucytosine (100 mg/kg/day) to (2) seven days amphotericin B deoxycholate (1 mg/kg/day) given alongside seven days of flucytosine (100 mg/kg/day) followed by seven days of fluconazole (1200 mg/day). The primary endpoint is all-cause mortality at ten weeks with a non-inferiority margin of 10% and 90% power. Secondary endpoints are early fungicidal activity, proportion of grade III/IV adverse events, pharmacokinetic parameters and pharmacokinetic/pharmacodynamic associations, health service costs, all-cause mortality within the first two and four weeks, all-cause mortality within the first ten weeks (superiority analysis) and rates of CM relapse, immune reconstitution inflammatory syndrome and disability at ten weeks. A total of 850 patients aged ≥ 18 years with a first episode of HIV-associated CM will be enrolled (425 randomised to each arm). All patients will be followed for 16 weeks. All patients will receive consolidation therapy with fluconazole 800 mg/day to complete ten weeks of treatment, followed by fluconazole maintenance and ART as per local guidance. Discussion A safe, sustainable and easy to administer regimen of L-AmB that is non-inferior to seven days of daily amphotericin B deoxycholate therapy may reduce the number of adverse events seen in patients treated with amphotericin B deoxycholate and shorten hospital admissions, providing a highly favourable and implementable alternative to the current WHO recommended first-line treatment. Trial registration ISRCTN, ISRCTN72509687. Registered on 13 July 2017.
- Published
- 2018
- Full Text
- View/download PDF
49. Feasibility of oral HIV self-testing in female sex workers in Gaborone, Botswana
- Author
-
Emily Shava, Laura M. Bogart, Kutlo Manyake, Charlotte Mdluli, Kamogelo Maribe, Neo Monnapula, Bornapate Nkomo, Mosepele Mosepele, Sikhulile Moyo, Mompati Mmalane, Till Bärnighausen, Joseph Makhema, and Shahin Lockman
- Subjects
Medicine ,Science - Abstract
Background Oral HIV self-testing (HIVST) may be useful for increasing testing in persons at elevated risk of acquiring HIV. Methods We conducted a pilot study to evaluate the feasibility (defined by uptake) of HIVST among FSW in Gaborone, Botswana. FSW age 18 years and above were recruited through a non-governmental organization serving FSW. FSW with unknown or negative HIV status at screening performed HIVST in the study clinic following brief training. FSW testing HIV-negative were each given two test kits to take home: one kit to perform unassisted HIVST and another to share with others. Feasibility (use) of HIVST (and sharing of test kits with others) was assessed in these women at a study visit four months later. Results Two hundred FSW were screened. Their average age was 34 years (range 18–59), and 115 (58%) were HIV-positive. Eighty-five (42%) tested HIV-negative at entry and were eligible to take part in the HIVST pilot study. All 85 (100%) agreed to take home HIVST kits. Sixty-nine (81%) of these 85 participants had a follow-up visit, 56 (81%) of whom reported performing HIVST at a mean of three and half months after the initial visit. All 56 participants who performed HIVST reported negative HIVST results. Fifty (73%) of the 69 participants who took HIVST kits home shared them with others. Of the 50 women sharing HIVST kits, 25 (50%) shared with their non-client partners, 15 with a family member, 8 with friends, and 3 with a client. One participant did not test herself but shared both her test kits. Most participants 53/56 (95%) found oral HIVST very easy to use whilst 3/56 (5%) felt it was fairly easy. Conclusion Oral HIVST is feasible among FSW in Gaborone, Botswana. The majority of FSW used the HIVST kits themselves and also shared extra HIVST kits with other individuals.
- Published
- 2021
50. Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans
- Author
-
Torgersen, Jessie, Bellamy, Scarlett L., Ratshaa, Bakgaki, Han, Xiaoyan, Mosepele, Mosepele, Zuppa, Athena F., Vujkovic, Marijana, Steenhoff, Andrew P., Bisson, Gregory P., and Gross, Robert
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.